Etg Warszawa Sp. z o.o.

Warsaw 68 trials 28 recruiting

68 Registered trials

28 Currently recruiting

Organisation

Etg Warszawa Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100040846

Address

Ul. Wynalazek 4, 02-677, Poland

Departments

.
#40604:ETG Neuroscience
#45006: ETG Warszawa
202-ETG Warszawa
2703: ETG Warszawa
2901 : Ortopedia
403_ETG Warszawa
40604: Dermatology
40604: ETG Warszawa
616009: ETG Warszawa
Dermatology
ETG Warszawa
General Medicine
N/A
NA
NA/ND
No Department
not applicable/nie dotyczy
Poradnie ETG Warszawa
Private Practice

Clinical trials at this site (68)

Search interface

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Cardiovascular disease 5 2023-02-28
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Moderate to Severe Plaque Psoriasis 5 2025-09-16
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
Once-weekly petrelintide versus placebo for obesity or overweight with comorbidities Ended

2024-512549-18-00 Weight management 4 2024-12-19
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 4 2024-04-10
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended

2022-502080-38-00 Moderate to severe rotator cuff tendinopathy 5 2023-10-16
A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended

2022-501988-40-00 RSV-associated (subtypes A and B) disease in adults age 5 2023-08-17
Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee. Ended

2024-515709-24-00 Moderate to severe pain associated with Osteoarthritis 5 2022-07-26
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18
Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended

2023-509937-37-00 Osteoarthritis 4 2021-07-21
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
A randomized, phase 3 multicenter clinical trial to confirm the clinical efficacy and evaluate the safety of linaprazan glurate compared to … Ended

2025-522750-39-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5